BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-767@pharmaconomics
DTSTAMP:20260707T030403Z
DTSTART;VALUE=DATE:20260205
DTEND;VALUE=DATE:20260206
SUMMARY:SPRB Phase 2 — tralesinidase alfa
DESCRIPTION:Phase 2 trial results for tralesinidase alfa in Sanfilippo Syndrome Type B (MPS IIIB) are due Feb 5\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1683553/000119312526039399/sprb-20260205.htm\n\nTrack it: https://pharmaconomics.com/e/767
URL:https://pharmaconomics.com/e/767
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SPRB catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR